These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 9190359)

  • 21. Hormonal treatment of endometrial cancer: past, present and future.
    Podczaski E; Mortel R
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis.
    Salvesen HB; Das S; Akslen LA
    Clin Cancer Res; 2000 Jan; 6(1):153-9. PubMed ID: 10656444
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Correlation between receptor status and results of treatment in endometrial carcinoma].
    Baĭnazarova AA; Iskakova ZhK
    Vopr Onkol; 2006; 52(6):654-8. PubMed ID: 17338243
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of erythropoietin expression in human endometrial carcinoma.
    Acs G; Xu X; Chu C; Acs P; Verma A
    Cancer; 2004 Jun; 100(11):2376-86. PubMed ID: 15160341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
    Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
    Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
    Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
    Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.
    Falcón O; Chirino R; León L; López-Bonilla A; Torres S; Fernández L; García-Hernández JA; Valerón PF; Díaz-Chico JC
    Br J Cancer; 1999 Feb; 79(3-4):570-6. PubMed ID: 10027332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral heterogeneity in colorectal carcinoma: trucut sampling for DNA ploidy analysis.
    Giovagnoli MR; Giarnieri E; Midiri G; Tesoriere A; Ferraro S; Vecchione A
    Anticancer Res; 1999; 19(5C):4577-80. PubMed ID: 10650813
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.
    Arnett-Mansfield RL; deFazio A; Wain GV; Jaworski RC; Byth K; Mote PA; Clarke CL
    Cancer Res; 2001 Jun; 61(11):4576-82. PubMed ID: 11389093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
    Ramondetta LM; Johnson AJ; Sun CC; Atkinson N; Smith JA; Jung MS; Broaddus R; Iyer RB; Burke T
    Cancer; 2009 May; 115(9):1867-74. PubMed ID: 19241422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium.
    Orejuela FJ; Ramondetta LM; Smith J; Brown J; Lemos LB; Li Y; Hollier LM
    Gynecol Oncol; 2005 May; 97(2):483-8. PubMed ID: 15863148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
    Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
    Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alpha, estrogen-beta and progesterone; a case controlled study.
    Wilder JL; Shajahan S; Khattar NH; Wilder DM; Yin J; Rushing RS; Beaven R; Kaetzel C; Ueland FR; van Nagell JR; Kryscio RJ; Lele SM
    Gynecol Oncol; 2004 Feb; 92(2):553-8. PubMed ID: 14766247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Progesterone receptors in patients with endometrial cancer].
    Gorchev G; Milkov V
    Akush Ginekol (Sofiia); 1993; 32(3):32-3. PubMed ID: 8037316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Rate of proliferation as a prognostic criterion in endometrial carcinoma--an immunohistochemical analysis with the monoclonal antibody KI-S1].
    Backe J; Gassel AM; Müller T; Schön S; Kaesemann H
    Zentralbl Gynakol; 1997; 119(7):334-42. PubMed ID: 9340973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study.
    Singh M; Zaino RJ; Filiaci VJ; Leslie KK
    Gynecol Oncol; 2007 Aug; 106(2):325-33. PubMed ID: 17532033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
    Engelsen IB; Stefansson IM; Akslen LA; Salvesen HB
    Am J Obstet Gynecol; 2008 Nov; 199(5):543.e1-7. PubMed ID: 18599012
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Microsatellite instability in endometrial neoplasms correlation with clinicopathologic parameters and estrogen receptor or progesterone receptor status].
    Song Y; Lang J
    Zhonghua Fu Chan Ke Za Zhi; 2000 May; 35(5):273-6. PubMed ID: 11775905
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
    Yemelyanova A; Vang R; Seidman JD; Gravitt PE; Ronnett BM
    Am J Surg Pathol; 2009 Jun; 33(6):914-24. PubMed ID: 19295407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia].
    Makarov OV; Sergeev PV; Sviridov NK; Kareva EN; Isaeva EG; Mgdesian KK; Kirpichnikova NV
    Vopr Onkol; 2000; 46(5):570-3. PubMed ID: 11202189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.